Prescription drug · ANDA
Dimethyl fumarate NDC 82249-747
Dimethyl fumarate 240 mg/1 · Capsule, Delayed release · Oral · CivicaScript LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 82249-747-60 | 82249074760 | 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE, PLASTIC (82249-747-60)Marketed from Jun 11, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Dimethyl fumarate
- Generic name (nonproprietary)
- dimethyl fumarate
- Active ingredients
- Dimethyl fumarate — 240 mg/1
- Dosage form
- Capsule, Delayed release
- Route
- Oral
- Labeler
- CivicaScript LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210440
- Marketing start
- Listing expires
- Identifiers
- Product ID 82249-747_ca6c6bda-05ac-4a39-8356-86bdfa61e863SPL ID ca6c6bda-05ac-4a39-8356-86bdfa61e863SPL set ID f3002b6a-841e-4247-9155-3acfb30cabcdRxCUI 1373483, 1373491UNII FO2303MNI2UPC 0382249747602
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N482249074760followed by a unit qualifier and the quantityPackage 82249-0747-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Dimethyl fumarate delayed-release capsules is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210440
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Dimethyl fumarate | Dimethyl fumarate 120 mg/1 | Capsule, Delayed releaseOral | CivicaScript LLC | 82249-745 |
| Dimethyl fumarate | Dimethyl fumarate 240 mg/1 | Capsule, Delayed releaseOral | Ascend Laboratories, LLC | 67877-556 |
| Dimethyl fumarate | Dimethyl fumarate 120 mg/1 | Capsule, Delayed releaseOral | Ascend Laboratories, LLC | 67877-555 |
| Dimethyl Fumarate | — | Kit | Ascend Laboratories, LLC | 67877-557 |